Jurox manufactures and distributes veterinary pharmaceutical products. It offers animal health products for cats, dogs, beef cattle, dairy cattle, horses, sheep, and pigs. The company was founded in 1992 and is based in Rutherford, New South Wales. In August 2021, Jurox was acquired by Zoetis. The terms of the transaction were not disclosed.
Missing: Jurox's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Jurox's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Jurox has filed 1 patent.
Food additives, Pharmaceutical industry, Phenols, Lactams, Excipients
Food additives, Pharmaceutical industry, Phenols, Lactams, Excipients
Latest Jurox News
Oct 12, 2022
News provided by Share this article Share this article Rising demand in safe and reliable reversal of sedative effects of dexmedetomidine and medetomidine propelling revenue size in atipamezole market; preference as injectable for dogs hinges on good tolerability Rising need for effective and safe anti-sedative solutions in pets underpins vast potential; pharmaceutical companies expanding online distribution networks to tap into thriving demand in North America WILMINGTON, Del. , Oct. 12, 2022 /PRNewswire/ -- Rising adoption of anti-sedative agents for safe and quick reversal of sedative effects induced by dexmedetomidine and medetomidine in pets is a key pivot for expansion of profitable avenue for companies in atipamezole market. A TMR study on the growth dynamics found that intramuscular route of administration is expected to be largest revenue generator in atipamezole market . The atipamezole market size is projected to reach US$ 70 million by the end of 2030. Growing regulatory approval of atipamezole solutions for injections in pets will spur future market demand for atipamezole market manufacturing. Veterinary hospitals are estimated to tap into the vast demand for atipamezole solutions in dogs and cats and other companion animals. On the other hand, the study authors observed that rise in investments by various pharmaceutical companies on expanding online pharmacies will also propel revenue streams. The TMR study found that leading players in atipamezole market are leaning on R&D for unveiling anti-sedation agents with high tolerability and effectiveness in recovery from anesthesia. Furthermore, drug manufacturers are taking initiatives in raising awareness of correct dosage of atipamezole and special precautions that pet owners and veterinarians need to exercise while administering the injections. Key Findings of Atipamezole Market Study Use as Anti-sedative Agents in Dogs and Cats Underpins Abundant Opportunities: Growing adoption of atipamezole in anti-sedative agents in dogs and cats is generating substantial growth opportunities for companies in the market. Especially in case of health dogs, the injections have demonstrated good tolerability, hence stoking the popularity of products. Educating clinicians of the contraindications will boost the outlook of the atipamezole market, opined the study. R&D on Enhancing Tolerability and Safety of Atipamezole Solutions for Reversal of Medetomidine-Induced Sedation: Ongoing clinical studies and R&D by pharmaceutical companies will pave the way for increasing the tolerability and safety of anesthetic reversal agents. Stridently, the efforts will lead to new revenue streams for firms in the atipamezole market. Massive Research Potential in Sleep Disorder Medications in Adults: Growing demand for medications for insomnia and sleep disorders is creating an incredible revenue potential in atipamezole market. Prevalence of sleep disorders in adults is catalyzing research on ant-sedative agents. Atipamezole Market: Key Drivers Growing spending on pet care in conjunction with growing ownership of pets in developing and developed regions is a key driver of atipamezole market. Of note, ongoing clinical trials pertaining to medications that address complications of prolonged anesthesia in wide variety of species in veterinary medicine is likely to create tremendous lucrative opportunity for pharmaceutical companies. R&D in sleep-inducing drugs for humans holds a massive potential, pivoting on the need for reducing prevalence of insomnia, will open up several new growth frontiers in atipamezole market. Atipamezole Market: Regional Growth Dynamics North America held a major share of the global atipamezole market in 2019. Rise in pet ownership over the past few years coupled with improving infrastructure of veterinary hospitals for companion animals has created massive revenue potential. In addition, rising spending on pet care in the U.S. has generated substantial lucrative demand for ant-sedative products in the region, thereby stirring the commercialization of atipamezole ingredients. Rise in demand for quality animal healthcare services is bolstering the prospects of the atipamezole market in North America. Atipamezole Market: Competition Landscape Multinational pharmaceutical companies in atipamezole market are reaping substantial revenue gains on the back of product approvals by regulatory agencies in various geographies. Key players are keenly expanding their product portfolio. Some of them are Troy Laboratories Pty Ltd, Forte Healthcare Ltd., Chanelle Pharma Group, Vetoquinol UK Ltd, Jurox Pty Limited, Orion Corporation, Modern Veterinary Therapeutics, and Merck & Co., Inc. Atipamezole Market Segmentation Middle East & Africa Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research: Anticoagulant Reversal Drugs Market : The global anticoagulant reversal drugs market is anticipated to reach more than US$ 2.3 Bn by the end of 2031 at a CAGR of 11.3% from 2022 to 2031. Macular Degeneration Treatment Market : The global macular degeneration treatment market is anticipated to reach more than US$ 21.1 Bn by the end of 2031 at a CAGR of 8.8% from 2022 to 2031. PET Radiotracer Market : The global PET radiotracer market is anticipated to reach more than US$ 3.2 Bn by the end of 2031 at a CAGR of 8.5% from 2022 to 2031. Gemcitabine HCL Market : The global gemcitabine HCl market is anticipated to reach more than US$ 1.3 Bn by 2031 at a CAGR of 7.8% from 2022 to 2031. Homeopathic Products Market : The global homeopathic products market is anticipated to reach more than US$ 32.4 Bn by the end of 2031 at a CAGR of 11.6% from 2022 to 2031. Pain Management Therapeutics Market : The global pain management therapeutics market is anticipated to reach more than US$ 98.0 Bn by the end of 2031 at a CAGR of 2.9% from 2022 to 2031. Peptide Therapeutics Market : The global peptide therapeutics market is anticipated to reach more than US$ 91.25 Bn by 2031 at a CAGR of 8.8% from 2022 to 2031. Collagen Peptide & Gelatin Market : The global collagen peptide and gelatin market is anticipated to reach more than US$ 7.8 Bn by the end of 2031 at a CAGR of 5.0% from 2022 to 2031. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services . Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyse information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ Contact
Jurox Frequently Asked Questions (FAQ)
When was Jurox founded?
Jurox was founded in 1992.
Where is Jurox's headquarters?
Jurox's headquarters is located at 85 Gardiner Street, Rutherford.
What is Jurox's latest funding round?
Jurox's latest funding round is Acquired.
Who are the investors of Jurox?
Investors of Jurox include Zoetis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.